Samrat Pharmachem Intrinsic Value
Samrat Pharmachem intrinsic value. Samrat Pharmachem (SAMRATPH) median intrinsic value is ₹453.33 from 3 valuation models (range ₹279–₹481), vs current price ₹240.40 — +88.6% upside (Trading Below Calculated Value), margin of safety 47.0%. Read SAMRATPH dividend yield for the complete payout history and dividend yield track record.
SAMRATPH Valuation Methods Summary — DCF, Graham Number & P/E
Samrat Pharmachem intrinsic value across 3 models vs current price ₹240.40 — upside/downside and value range per method. For current market price and key ratios, visit SAMRATPH stock price BSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹453.33 | ₹408.00 - ₹498.66 | +88.6% | Book Value/Share: ₹226.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹480.80 | ₹432.72 - ₹528.88 | +100.0% | Revenue/Share: ₹983.33, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹278.51 | ₹222.81 - ₹334.21 | +15.9% | CF Growth: 5.0%, Discount: 15% |
SAMRATPH Intrinsic Value vs Market Price — All Valuation Models
Samrat Pharmachem fair value range ₹279–₹481 vs current market price ₹240.40 across 3 valuation models. Compare with SAMRATPH fundamental valuation to assess whether the stock is under or overvalued.
SAMRATPH Intrinsic Value Analysis — Undervalued or Overvalued?
Samrat Pharmachem median intrinsic value ₹453.33, current price ₹240.40 — Trading Below Calculated Value by 88.6%, margin of safety 47.0%.
What is the intrinsic value of SAMRATPH?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Samrat Pharmachem (SAMRATPH) is ₹453.33 (median value). With the current market price of ₹240.40, this represents a +88.6% variance from our estimated fair value.
The valuation range spans from ₹278.51 to ₹480.80, indicating ₹278.51 - ₹480.80.
Is SAMRATPH undervalued or overvalued?
Based on our multi-method analysis, Samrat Pharmachem (SAMRATPH) appears to be trading below calculated value by approximately 88.6%.
SAMRATPH Financial Health — Key Ratios vs Industry Benchmarks
Samrat Pharmachem financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | -2.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 2.38x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
SAMRATPH Cash Flow Quality — Operating & Free Cash Flow
Samrat Pharmachem operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹9 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-9 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹18 Cr | ₹18 Cr | Positive Free Cash Flow | 8/10 |